{"id":4735,"date":"2021-09-22T18:50:31","date_gmt":"2021-09-22T16:50:31","guid":{"rendered":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/?p=4735"},"modified":"2021-10-07T17:23:04","modified_gmt":"2021-10-07T15:23:04","slug":"lskdjsknl","status":"publish","type":"post","link":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/lskdjsknl\/","title":{"rendered":"Teletrabajo"},"content":{"rendered":"\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"318\" height=\"159\" src=\"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-content\/blogs.dir\/6\/files\/sites\/76\/2021\/07\/descarga.jpg\" alt=\"Descarga\" class=\"wp-image-4504\" srcset=\"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-content\/blogs.dir\/6\/files\/sites\/76\/2021\/07\/descarga.jpg 318w, https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-content\/blogs.dir\/6\/files\/sites\/76\/2021\/07\/descarga-300x150.jpg 300w\" sizes=\"auto, (max-width: 318px) 100vw, 318px\" \/><\/figure><\/div>\n\n\n\n<p class=\"has-text-align-justify\">Como os explicamos en anteriores comunicados, el pasado mes de julio hicimos llegar a RRHH una propuesta de acuerdo&nbsp;para aplicar la legislaci\u00f3n vigente en materia de teletrabajo y mejorarla en ciertos aspectos.<\/p>\n\n\n\n<p class=\"has-text-align-justify\">Las conversaciones con RRHH han sido positivas, aproximando posturas y alcanzado un razonable entendimiento entre&nbsp;ambas partes, si bien, debido a la importancia de la cuesti\u00f3n, se est\u00e1 retrasando m\u00e1s de lo que hab\u00edamos previsto.<\/p>\n\n\n\n<p class=\"has-text-align-justify\">Esperamos poder cerrar el tema lo antes posible e informaros de todos los detalles, mientras esto llega, nos ponemos a vuestra disposici\u00f3n para resolver&nbsp;cualquier duda que teng\u00e1is.<\/p>\n\n\n\n<hr class=\"wp-block-separator\" \/>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"551\" height=\"89\" src=\"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-content\/blogs.dir\/6\/files\/sites\/76\/2021\/06\/ccoo-t-p.jpg\" alt=\"Ccoo T P\" class=\"wp-image-4304\" srcset=\"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-content\/blogs.dir\/6\/files\/sites\/76\/2021\/06\/ccoo-t-p.jpg 551w, https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-content\/blogs.dir\/6\/files\/sites\/76\/2021\/06\/ccoo-t-p-300x48.jpg 300w\" sizes=\"auto, (max-width: 551px) 100vw, 551px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Como os explicamos en anteriores comunicados, el pasado mes de julio hicimos llegar a RRHH una propuesta de acuerdo&nbsp;para aplicar la legislaci\u00f3n vigente en materia de teletrabajo y mejorarla en &#8230; <a title=\"Teletrabajo\" class=\"read-more\" href=\"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/lskdjsknl\/\" aria-label=\"Leer m\u00e1s sobre Teletrabajo\">Leer m\u00e1s<\/a><\/p>\n","protected":false},"author":59,"featured_media":4504,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25,26],"tags":[],"class_list":["post-4735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notesinformatives","category-notesinformatives_ca","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33"],"_links":{"self":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/4735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/users\/59"}],"replies":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/comments?post=4735"}],"version-history":[{"count":4,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/4735\/revisions"}],"predecessor-version":[{"id":4740,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/4735\/revisions\/4740"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/media\/4504"}],"wp:attachment":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/media?parent=4735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/categories?post=4735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/tags?post=4735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}